BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32824580)

  • 1. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
    Riedl JM; Barth DA; Brueckl WM; Zeitler G; Foris V; Mollnar S; Stotz M; Rossmann CH; Terbuch A; Balic M; Niedrist T; Bertsch T; Stoeger H; Pichler M; Olschewski H; Absenger G; Ficker JH; Gerger A; Posch F
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
    Lang D; Brauner A; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Kaiser B; Greil R; Lamprecht B
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
    Naqash AR; McCallen JD; Mi E; Iivanainen S; Marie MA; Gramenitskaya D; Clark J; Koivunen JP; Macherla S; Jonnalagadda S; Polsani S; Jiwani RA; Hafiz M; Muzaffar M; Brunetti L; Stroud CRG; Walker PR; Wang K; Chung Y; Ruppin E; Lee SH; Yang LV; Pinato DJ; Lee JS; Cortellini A
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
    Zheng X; Zhang L; Wu L; Zhao J; Sun J; Fang Y; Zhou J; Chu Q; Shen Y; Yang Z; Chen L; Huang M; Lin X; Liu Z; Shen P; Wang Z; Wang X; Wang H; Han Z; Liu A; Zhang H; Ye F; Gao W; Wu F; Song Z; Chen S; Zhou C; Wang Q; Xu C; Huang D; Zheng X; Miao Q; Jiang K; Xu Y; Wu S; Wang H; Zhang Q; Yang S; Li Y; Chen S; Lin G
    BMC Cancer; 2023 Dec; 23(1):1244. PubMed ID: 38104105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
    Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
    Klümper N; Saal J; Berner F; Lichtensteiger C; Wyss N; Heine A; Bauernfeind FG; Ellinger J; Brossart P; Diem S; Schmid S; Joerger M; Frueh M; Ritter M; Hölzel M; Flatz L; Bald T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
    Öjlert ÅK; Nebdal D; Lund-Iversen M; Åstrøm Ellefsen R; Brustugun OT; Gran JM; Halvorsen AR; Helland Å
    Acta Oncol; 2021 Feb; 60(2):149-156. PubMed ID: 33356733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
    Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
    Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
    Klümper N; Sikic D; Saal J; Büttner T; Goldschmidt F; Jarczyk J; Becker P; Zeuschner P; Weinke M; Kalogirou C; Breyer J; Burger M; Nuhn P; Tully K; Roghmann F; Bolenz C; Zengerling F; Wirtz RM; Muders M; Kristiansen G; Bald T; Ellinger J; Wullich B; Hölzel M; Hartmann A; Erben P; Ritter M; Eckstein M
    Eur J Cancer; 2022 May; 167():13-22. PubMed ID: 35366569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Wei Y; Xu J; Huang X; Xie S; Lin P; Wang C; Guo Y; Zou S; Zhao Z; Wen W; Song Y; Bao Z; Zhang L; Liu W; Kong W; Wang W; He B; Zhang S; Zhou C; Chen Y; Yu Z
    J Thorac Dis; 2023 Apr; 15(4):1892-1900. PubMed ID: 37197527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.
    Iivanainen S; Ahvonen J; Knuuttila A; Tiainen S; Koivunen JP
    ESMO Open; 2019; 4(4):e000531. PubMed ID: 31555483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 17. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
    Front Immunol; 2022; 13():827788. PubMed ID: 35211122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Topolcan O; Racek J; Minarik M; Benesova L; Bortlicek Z; Poprach A; Buchler T
    Tumour Biol; 2015 Dec; 36(12):9215-22. PubMed ID: 26088452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Wang H; Zhou F; Qiao M; Li X; Zhao C; Cheng L; Chen X; Zhou C
    Front Oncol; 2021; 11():671874. PubMed ID: 34367957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
    Qiu Y; Jiang J; Zhang M; Qin Y
    Oncol Lett; 2019 Jul; 18(1):161-168. PubMed ID: 31289485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.